Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GDUFA II Reviews Start Strong With High First-Cycle Approval Rate

Dec 04 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

May 16 2017

New ANDA Review Pathways: Should You Be A Priority Or Expedited?

Nov 13 2017

FDA Contradicts AAM's Generic Market Consolidation Argument

Nov 21 2017

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Additional Topics

United States Generic Drugs Review Pathway Regulation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window